Intra-Cellular Therapies (ITCI) Tops Q1 EPS by 14c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q1 EPS of ($0.64), $0.14 better than the analyst estimate of ($0.78).

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• Yum! Brands (YUM) PT Lowered to $180 at Argus
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30